In this paper we report on the molecular defect underlying apolipoprotein CII (apoCII) deficiency in an Italian kindred. ApoCII serves as cofactor for lipoprotein lipase (LPL) in triglyceride hydrolysis of chylomicrons and very low density lipoproteins. Homozygous apoCII deficiency manifests with type I hyperlipoproteinaemia and is a rare disorder of lipoprotein metabolism. Until now, only 10 kindreds with apoCII deficiency have been published and all underlying mutations were unique.
The hydrolysis of the triacylglycerol core of circulating chylomicrons and very low density lipoproteins (VLDL) requires the presence of the plasma enzyme lipoprotein lipase (LPL) and its cofactor apolipoprotein (apo) CII Studies using either proteolytic fragments or synthetic peptides are suggestive of the presence of different functional domains in the mature protein. The N-terminal part of the protein seems to mediate lipoprotein binding, probably through amphipathic helix interaction with phospholipids. The C-terminal domain of apoCII has been suggested as the main site for LPL activation (residue 54 to 63) and for binding to LPL (residue 64 to 79).4 Not all studies, however, support these conclusions.5
The gene encoding for apoCII maps to the long arm of chromosome 19 (19ql3) and the complete nucleic acid sequence and genomic organisation have been elucidated.67
ApoCII deficiency is a rare hereditary disorder, inherited as an autosomal recessive trait. The clinical manifestations of apoCII deficiency are identical to those of LPL deficiency and include upper abdominal pain, eruptive xanthomatas, lipaemia retinalis, and recurrent pancreatitis. ApoCII deficiency was first described in 1978.8 Since then 10 different genetic defects underlying apoCII deficiency in different parts of the world have been determined. 9 Here we report the molecular basis of functional apoCII deficiency in an Italian kindred from Sicily. We show a C-+A transition, resulting in the introduction of a stop codon for Tyr37, which is identical to a previously reported mutation from another family with origins in a distant region. We suggest therefore that this mutation might be a frequent cause of apoCII deficiency in patients of Italian descent.
Material and methods

CASE 1
The index patient (II.5) is a 43 year old male of Sicilian origin. The patient was first seen when he was 
LIPOPROTEIN ANALYSIS
Lipoproteins were separated by ultracentrifugation as previously described" and washed once at the upper density limit. Cholesterol and triglycerides were measured by standard enzymatic techniques,'2 13 using reagents from Boehringer-Mannheim (Dorval, Quebeq, Canada). The Corning ACI system was used for lipoprotein electrophoresis.
Apolipoprotein B was measured in isolated lipoproteins by tetramethylurea (TMU) treatment or by electroimmunoassay.'4'5 Apolipoprotein AI and AII standards were purified by gel chromatography in the presence of 6 mol/l urea. 16 
DNA ANALYSIS
Polymerase chain reaction Genomic DNA was extracted from the buffycoat of 30 ml EDTA anticoagulated blood of the index patient and his available family members, for analysis by the polymerase chain reaction (PCR).
The reactions were performed in a DNA thermocycler (Perkin-Elmer Cetus, Norwalk, CT, USA) using the buffer recommended by the manufacturer in conjunction with 15 The ligation products were then transformed into the recommended INVaF' cells and incubated for 12 to 14 hours at 37'C on LB agar plates containing kanamycine and X-gal. The following day, six independent white colonies were isolated and grown overnight in LB medium for DNA isolation purposes. Small amounts of the extracted plasmid DNA were digested with HindIII and EcoRI to determine the size of the inserted fragments.
Positive samples were subjected to double stranded DNA sequencing using the Sequenase version 2.0 (US Biochemicals, Cleveland, OH) after annealing of 1 pmol of the required "nested" PCR primer according to the ligated exon. Annealing was performed by heating for two minutes at 65'C and cooling down until room temperature was reached. The labelling reaction took place at 4'C for five minutes followed by termination for five minutes at 39'C. These samples were loaded on a 6% polyacrylamide 5 mol/l urea sequencing gel and electrophoresed at 55'C for two hours at 1900 V.
Mutation detection using RsaI restriction endonuclease Exon 3 of all family members was separately group 
